The Role of FLT3 Inhibitors As Maintenance Therapy Following Hematopoietic Stem Cell Transplant

Overview

Journal Leuk Res Rep

Date 2018 Aug 17

PMID 30112274

Citations 5

Authors

Grace Xiuqing Li

Lan Wang

Bassam Yaghmour

Giridharan Ramsingh

George Yaghmour

Affiliations

Soon will be listed here.

Abstract

Activating mutations in FLT3 in acute myeloid leukemia (AML) portend a poor prognosis, and targeting FLT3 with a tyrosine kinase inhibitor has been an area of intense research recently. Most FLT3 mutated AML patients undergo hematopoietic stem cell transplantation (HSCT) as standard of care but a significant proportion of patients relapse. Although the use of FLT3 inhibitors in the pre-HSCT perspective is more clearly defined, its use in the post-HSCT scenario, when most relapses occur, remains unclear. In this review, we comprehensively present the data on the recent and ongoing studies evaluating the role of various FLT3 inhibitors in AML with a particular focus in the post-HSCT setting.

Citing Articles

Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes.

Griffin J, Song Y, Yang H, Freimark J, Shah M Eur J Haematol. 2021; 107(5):553-565.

PMID: 34289175 PMC: 9292256. DOI: 10.1111/ejh.13692.

Two Novel Mutations in a Turkish Patient with Acute Myeloid Leukemia.

Tokgun P, Alay M, Atli Tekin S, Guler N, Tokgun O, Demiray A Balkan J Med Genet. 2021; 23(2):99-102.

PMID: 33816079 PMC: 8009566. DOI: 10.2478/bjmg-2020-0024.

Gilteritinib induces PUMA-dependent apoptotic cell death via AKT/GSK-3β/NF-κB pathway in colorectal cancer cells.

Li L, Lin L, Li M, Li W J Cell Mol Med. 2019; 24(3):2308-2318.

PMID: 31881122 PMC: 7011145. DOI: 10.1111/jcmm.14913.

The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy.

Mendez L, Posey R, Pandolfi P Front Oncol. 2019; 9:1162.

PMID: 31781488 PMC: 6856667. DOI: 10.3389/fonc.2019.01162.

Quizartinib (AC220): a promising option for acute myeloid leukemia.

Zhou F, Ge Z, Chen B Drug Des Devel Ther. 2019; 13:1117-1125.

PMID: 31114157 PMC: 6497874. DOI: 10.2147/DDDT.S198950.

References

Wander S, Levis M, Fathi A . The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol. 2014; 5(3):65-77. PMC: 4031904. DOI: 10.1177/2040620714532123. View

Antar A, Otrock Z, El-Cheikh J, Kharfan-Dabaja M, Battipaglia G, Mahfouz R . Inhibition of FLT3 in AML: a focus on sorafenib. Bone Marrow Transplant. 2016; 52(3):344-351. DOI: 10.1038/bmt.2016.251. View

Schiller G, Tuttle P, Desai P . Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation. Biol Blood Marrow Transplant. 2016; 22(6):982-990. DOI: 10.1016/j.bbmt.2016.01.013. View

Nagel G, Weber D, Fromm E, Erhardt S, Lubbert M, Fiedler W . Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017; 96(12):1993-2003. PMC: 5691091. DOI: 10.1007/s00277-017-3150-3. View

Chen Y, Huang Y, Reiberger T, Duyverman A, Huang P, Samuel R . Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology. 2013; 59(4):1435-47. PMC: 3966948. DOI: 10.1002/hep.26790. View

Davids M, Kim H, Bachireddy P, Costello C, Liguori R, Savell A . Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016; 375(2):143-53. PMC: 5149459. DOI: 10.1056/NEJMoa1601202. View

Yafour N, Beckerich F, Bulabois C, Chevallier P, Daguindau E, Dumesnil C . How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome. Curr Res Transl Med. 2017; 65(2):65-69. DOI: 10.1016/j.retram.2017.06.001. View

Goodyear O, Dennis M, Jilani N, Loke J, Siddique S, Ryan G . Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012; 119(14):3361-9. DOI: 10.1182/blood-2011-09-377044. View

Berman E, Maloy M, Devlin S, Jhanwar S, Papadopoulos E, Jakubowski A . Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation. Leuk Res. 2015; 40:33-7. PMC: 5053396. DOI: 10.1016/j.leukres.2015.11.010. View

10.

Sharma M, Ravandi F, Bayraktar U, Chiattone A, Bashir Q, Giralt S . Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011; 17(12):1874-7. PMC: 4061979. DOI: 10.1016/j.bbmt.2011.07.011. View

11.

Ravandi F, Cortes J, Jones D, Faderl S, Garcia-Manero G, Konopleva M . Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010; 28(11):1856-62. PMC: 2930809. DOI: 10.1200/JCO.2009.25.4888. View

12.

Bornhauser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C . Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood. 2007; 109(5):2264-5. DOI: 10.1182/blood-2006-09-047225. View

13.

Knapper S, Burnett A, Littlewood T, Kell W, Agrawal S, Chopra R . A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006; 108(10):3262-70. DOI: 10.1182/blood-2006-04-015560. View

14.

Gallogly M, Lazarus H, Cooper B . Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis. Ther Adv Hematol. 2017; 8(9):245-261. PMC: 5639976. DOI: 10.1177/2040620717721459. View

15.

Walker A, Wang H, Walsh K, Bhatnagar B, Vasu S, Garzon R . Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2016; 57(9):2100-8. PMC: 5360182. DOI: 10.3109/10428194.2015.1135435. View

16.

Campregher P, de Mattos V, Salvino M, Souza Santos F, Hamerschlak N . Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases. Einstein (Sao Paulo). 2017; 15(3):355-358. PMC: 5823052. DOI: 10.1590/S1679-45082017RC3784. View

17.

Sammons S, Pratz K, Smith B, Karp J, Emadi A . Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. Am J Hematol. 2014; 89(9):936-8. PMC: 4144402. DOI: 10.1002/ajh.23782. View

18.

Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A . Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009; 113(26):6567-71. DOI: 10.1182/blood-2009-03-208298. View

19.

Ramsingh G, Westervelt P, McBride A, Stockerl-Goldstein K, Vij R, Fiala M . Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. Int J Hematol. 2014; 99(3):272-8. PMC: 4406413. DOI: 10.1007/s12185-014-1503-4. View

20.

Knapper S, Russell N, Gilkes A, Hills R, Gale R, Cavenagh J . A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood. 2016; 129(9):1143-1154. PMC: 5364440. DOI: 10.1182/blood-2016-07-730648. View